Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. RLYB212, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback